Daniel M. Junius Sells 46,667 Shares of ImmunoGen, Inc. (IMGN) Stock

ImmunoGen, Inc. (NASDAQ:IMGN) Director Daniel M. Junius sold 46,667 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $10.01, for a total value of $467,136.67. Following the completion of the sale, the director now directly owns 243,367 shares in the company, valued at $2,436,103.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

ImmunoGen, Inc. (NASDAQ:IMGN) traded down $0.74 during trading hours on Wednesday, reaching $9.80. The company had a trading volume of 5,240,200 shares, compared to its average volume of 3,304,313. The firm has a market capitalization of $1,394.58, a price-to-earnings ratio of -9.61 and a beta of 2.50. The company has a quick ratio of 2.78, a current ratio of 2.81 and a debt-to-equity ratio of -0.03. ImmunoGen, Inc. has a fifty-two week low of $2.40 and a fifty-two week high of $10.66.

ImmunoGen (NASDAQ:IMGN) last posted its earnings results on Friday, February 9th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The business had revenue of $39.40 million during the quarter, compared to analysts’ expectations of $39.62 million. The company’s revenue was up 185.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.39) EPS. sell-side analysts anticipate that ImmunoGen, Inc. will post -1.01 EPS for the current fiscal year.

IMGN has been the topic of several research analyst reports. Zacks Investment Research raised ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a research note on Tuesday, October 31st. BidaskClub raised ImmunoGen from a “hold” rating to a “buy” rating in a research note on Thursday, January 18th. HC Wainwright set a $18.00 price objective on ImmunoGen and gave the company a “buy” rating in a research note on Monday. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $5.00 price objective on shares of ImmunoGen in a research note on Friday, November 3rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $12.00 price objective on shares of ImmunoGen in a research note on Thursday, February 8th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. ImmunoGen currently has a consensus rating of “Buy” and an average price target of $9.10.

Institutional investors have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership bought a new position in ImmunoGen in the second quarter valued at about $102,000. Intl Fcstone Inc. bought a new position in ImmunoGen in the second quarter valued at about $115,000. Raymond James Financial Services Advisors Inc. bought a new position in ImmunoGen in the second quarter valued at about $126,000. Virginia Retirement Systems ET AL bought a new position in ImmunoGen in the third quarter valued at about $136,000. Finally, SG Americas Securities LLC raised its position in ImmunoGen by 75.7% in the fourth quarter. SG Americas Securities LLC now owns 18,416 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 7,937 shares during the last quarter. Hedge funds and other institutional investors own 67.97% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Daniel M. Junius Sells 46,667 Shares of ImmunoGen, Inc. (IMGN) Stock” was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2018/02/14/daniel-m-junius-sells-46667-shares-of-immunogen-inc-imgn-stock.html.

About ImmunoGen

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply